MondegarAI
Column Group LLC

Q3 2024 · 13F-HR

Column Group LLCholdings as filed

Filed 2024-11-14 · accession 0000950123-24-011839

$69.6M
Reported value
6
Positions
2024-09-30
Period end
View analyzed profile →PRO

The Brief · Column Group LLC · Q3 2024

AI · grounded in 13F

Column Group LLC reported no changes to its 13F holdings for 2024-09-30 relative to 2024-06-30.

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
68622P109ORICORIC Pharmaceuticals Inc.$36.3M52.2%3,540,777CommonSOLE
87990A106TNYATenaya Therapeutics, Inc.$18.1M26.1%9,400,290CommonSOLE
86889P109Surrozen, Inc.$9.7M13.9%810,088CommonSOLE
75382E109RAPT Therapeutics Inc$5.4M7.74%2,680,621CommonSOLE
786700104SGMTSagimet Biosciences Inc.$47,5580.07%17,169CommonSOLE
76155X100RVMDRevolution Medicines Inc$2,0860.00%46CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.